Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

More than 40 tyrosine kinase inhibitors (TKIs) have received hematological or oncological indications over the past 20 years, following the approval of imatinib, and many others are currently being tested in clinical and preclinical level. Beyond their common toxicities, no certain agent from this l...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziogas, Dimitrios C., Mandellos, Dimitrios, Theocharopoulos, Charalampos, Lialios, Panagiotis-Petros, Bouros, Spyros, Ascierto, Paolo A., Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554100/
https://www.ncbi.nlm.nih.gov/pubmed/34722270
http://dx.doi.org/10.3389/fonc.2021.727010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554100/
https://www.ncbi.nlm.nih.gov/pubmed/34722270
http://dx.doi.org/10.3389/fonc.2021.727010

Ejemplares similares